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Melioidosis is a neglected tropical disease with high mortality rate. It is caused by the
Gram-negative, CDC category B select agent Burkholderia pseudomallei (B. ps) that
is intrinsically resistant to first-line antibiotics. An antibody-based vaccine is likely to
be the most effective control measure. Previous studies have demonstrated significant
mechanistic roles of antibodies in protection against death in animal models, but data
from human melioidosis is scarce. Herein, we used in-vitro antibody-dependent cellular
phagocytosis and growth inhibition assays to assess the mechanism of protective
antibodies in patients with acute melioidosis. We found that serum from patients
who survived the disease enable more live B. ps to be engulfed by THP-1 derived
macrophages (median 1.7× 103 CFU/ml, IQR 1.1× 103-2.5× 103 CFU/ml) than serum
from patients who did not survive (median 1.2 × 103 CFU/ml, IQR 0.7 × 103-1.8 ×
103, p = 0.02). In addition, the intracellular growth rate of B. ps pre-opsonized with
serum from survivors (median 7.89, IQR 5.58–10.85) was diminished when compared
with those with serum from non-survivors (median 10.88, IQR 5.42–14.88, p = 0.04).
However, the difference of intracellular bacterial growth rate failed to reach statistical
significance when using purified IgG antibodies (p = 0.09). These results provide new
insights into a mechanistic role of serum in protection against death in human melioidosis
for antibody-based vaccine development.
Keywords: melioidosis, functional antibodies, opsonization, phagocytosis, Burkholderia pseudomallei, growth
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INTRODUCTION
Melioidosis is well-recognized as a major cause of fatal
community-acquired septicemia in northeast Thailand and
north Australia (Chaowagul et al., 1989; Currie et al., 2000).
The case fatality rate can exceed 40% in endemic regions.
Melioidosis is now known to be endemic in at least 45
countries across tropical areas, and 89,000 global deaths per
annum are estimated (Limmathurotsakul et al., 2016). The
causative agent of melioidosis is the facultative intracellular
Gram-negative bacillus Burkholderia pseudomallei (B. ps),
which is intrinsically resistant to commonly used antibiotics.
Prolonged antibiotic regimens are required to control the
infection. Highly effective vaccines against other polysaccharide-
encapsulated bacteria including Streptococcus pneumoniae,
Neisseria meningitides, and Haemophilus influenzae type b
rely on antibody-mediated protection (Snape et al., 2008;
Pollard et al., 2009; Wahid et al., 2014), hence antibody-based
vaccines are one of the most promising approaches to control B.
ps infection.
Various studies have reported an association between
protection against melioidosis and humoral immune responses
in animal models (Scott et al., 2013; Silva et al., 2013; Burtnick
et al., 2018; Khakhum et al., 2019); however, mechanistic roles of
the protective antibodies against melioidosis in humans have not
been well-elucidated.
The role of antibody quantity in protection against
human melioidosis is uncertain. High antibody titers
against whole cell B. ps antigens were not associated with
protection in melioidosis patients (Norazah et al., 1996;
Chaichana et al., 2018). Besides, high background titers in
individuals living in endemic regions makes interpretation not
straight-forward (Ho et al., 1997; Chaichana et al., 2018).
However, a recent research has reported a correlation
between survival and high levels of antibodies specific to
lipopolysaccharide (LPS) II (Charuchaimontri et al., 1999) and
Hemolysin co-regulated protein 1 (Hcp1) (Pumpuang et al.,
2019).
Antibody titers alone do not always account for protective
immunity. Therefore, this study aimed to adopt in vitro-
based approaches to measure the functional roles of
antibodies associated with protection against death in acute
human melioidosis.
MATERIALS AND METHODS
Ethics Statement
The study was approved by the ethics committees of the
Faculty of Tropical Medicine, Mahidol University (Submission
number TMEC 12-014); of Sunpasithiprasong Hospital, Ubon
Ratchathani (reference 018/2555); and the Oxford Tropical
Research Ethics Committee (reference 64-11). The study was
conducted according to the principles of the Declaration
of Helsinki (2008), and the International Conference on
Harmonization (ICH) Good Clinical Practice (GCP) guidelines.
Written informed consent was obtained for all patients enrolled
in the study.
Serum Sample Collection From Acute
Melioidosis Patients
Two hundred adult in-patients with acute melioidosis aged >
18 years old at Sunpasithiprasong Hospital, Ubon Ratchathani,
Thailand were enrolled, at a median of 5 days (interquartile range
(IQR) 3–6, range 2–13) after admission, as described previously
(Jenjaroen et al., 2015). Blood, sputum, throat, endotracheal,
bronchoalveolar lavage, pus, or urine were collected on the day
of enrollment for bacteria isolation. Melioidosis was defined as
isolation of B. ps from any clinical sample. Serum and plasma
were separated from blood after centrifugation of clotted and
heparinized blood, respectively, before aliquoted and stored at
−80◦C until used. The 28-days case fatality rate in this cohort
was 26%. Healthy control subjects with no diabetes or other
medical problem were recruited from the blood donation clinic
at Sunpasitthiprasong Hospital. Age range of healthy subjects
were from 28 to 73 years old (median 44, IQR 41–52). 23/50
of healthy subjects who have indirect hemagglutination assay
(IHA) titer was <1:10 were selected as seronegative controls
for melioidosis. 136/200 patients in the melioidosis cohort had
sufficient stored serum for assays (n = 94 for survivors and n =
42 for non-survivors).
Cell Lines and Bacteria Cultures
The humanmonocyte (THP-1) cell line was cultured in complete
medium (10%FCS RPMI-1640) at 37◦C with 5% CO2 for 2
days before used in the assays. To generate THP-1 derived
macrophage-like cells, THP-1 cells were incubated with 1µM
Phorbol 12-myristate 13-acetate (PMA, Sigma, Germany) for 3
days. The cells were then washed three times to remove PMA,
and rested in complete medium for 3 days before use.
B. ps strain K96243 (from frozen stock) was spread onto
Columbia agar and incubated at 37◦C. The overnight culture
from a single colony was grown in tryptone-soy broth (TSB)
and incubated overnight at 37◦C with shaking at 200 rpm. Then,
the culture was diluted with TSB to achieve an OD600 of 0.05,
and further incubated at 37◦C shaking until it reached log-phase
(OD600 of 0.6). The bacteria were washed 3 times with PBS and
kept at−80◦C in aliquots until used.
IgG Purification
Total IgG antibodies were individually purified from 100 µl
of the plasma of each melioidosis patient in the cohort via
negative selection using MelonTM Gel IgG Spin Purification
Kit (Thermo Scientific, MA) according to the manufacturer’s
protocol. After purification, 82/136 patients in the cohort had
sufficient concentration (≥ 3 mg/ml) of the antibodies for assays
(n= 55 for survivors and n= 27 for non-survivors).
Antibody-Dependent Cellular Phagocytosis
(ADCP) Assay
Frozen log-phase B. ps was thawed, washed and incubated with
fluorescein isothiocyanate (FITC) dye for 1 h at 37◦C in the dark.
The FITC-labeled B. ps was then washed thoroughly with PBS
3 times. Live B. ps, unlabeled or FITC-labeled, were incubated
with heat-inactivated (56◦C, 30min) patient serum (10% v/v),
purified IgG (0.5 mg/ml) or RPMI-1640 (control) at 37◦C for
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30min. The B. ps and antibody or control mixtures were then
added to THP-1 cells at a ratio of 5 colony forming units
(CFUs)/cell. After a 15-min incubation at 37◦C, the co-culture
mixtures were immediately chilled on ice to stop phagocytosis.
The cells were washed twice with PBS, and incubated with
chilled trypan blue (Sigma) at 4◦C for 15min to quench the
FITC signal of cell surface-bound B. ps (Busetto et al., 2004).
The cells were then washed twice with PBS and incubated with
CytofixTM fixation buffer (BD Bioscience, CA, USA) at 4◦C
for 15min. After washing the cells were resuspended in cold
MACSQuant Running Buffer (Miltenyi Biotec, Germany), and
analyzed by flow cytometry using the MACSQuant R© Analyzer
10 (Miltenyi Biotec). Results are expressed as Phagocytic index,
as described below:
Phagocytic index =
% infected cell in the presence of antibodies
% infected cell in the absence of antibodies
(1)
Growth Inhibition Assay
The unlabeled B. ps-antibody mixtures as described above were
added to THP-1 derived-macrophages a ratio of 0.01 CFU/cell
and further incubated for 1 h. In case of purified IgG, the
unlabeled B. ps was incubated with purified antibodies at the
concentration of 0.5 mg/ml for 30min at 37◦C before transferred
to the cells. The extracellular bacteria were killed by a 2-h
incubation in 500µg/ml of kanamycin. At selected time points,
the infected cells were washed and lysed with 1% saponin (Sigma)
in PBS. The intracellular bacteria were diluted in sterile water
and plated onto Columbia agar. The CFUs were counted and
expressed as CFU/ml. Bacterial survival is expressed as growth
rate of bacteria at 7 h compared with 3 h-post infection.
Growth rate =
(CFU
ml
at 7 h post infection)− (CFU
ml
at 3 h post infection)
CFU
ml
at 3 h post infection
(2)
Statistical Analysis
Non-normally distributed continuous data were reported as
median and interquartile range (IQR). The significance of
differences between two groups was analyzed by Mann-Whitney
U-test in GraphPad Prism 7 for Windows (GraphPad Software,
San Diego, CA, USA).
RESULTS
Survivors of Melioidosis Have Elevated
ADCP Activity Compared to Non-survivors
ADCP is important for the clearance of bacterial infection;
thus, we initially determined the opsonophagocytic activities
of antibodies derived from patients in a monocyte cell line
using flow cytometry. Serum samples were collected from acute
melioidosis patients at a median of 5 days after admission, and
antibodies against B. ps antigens in the serum were measured
by ELISA. The median absorbance value (OD450) of IgG against
heat-killed whole cell B. ps in survivors and non-survivors
FIGURE 1 | Comparison of in-vitro antibody-dependent cellular phagocytosis
(ADCP) activity of serum derived from acute melioidosis patients who survived
the disease (upward open triangles), acute melioidosis fatal cases (downward
open triangles) and healthy endemic controls (open circle). (A) The ADCP
activity in human monocyte THP-1 cells were determined by flow cytometry
and expressed as phagocytic index (described in Material and Methods).
(B) The ADCP activity of antibodies was also determined in THP-1-derived
macrophages using the colony count method to detect live bacteria inside
infected cells. The statistical test used for comparison is the Kruskal-Wallis
one-way ANOVA for more than two groups, and Mann-Whitney U for two
groups.
was comparable (Chaichana et al., submitted manuscript). The
phagocytic index of serum from healthy controls containing
undetectable level of B. ps-specific antibodies was significantly
lower than that from melioidosis patients (both survivors and
non-survivors). We observed a significantly greater phagocytic
index in serum samples derived from melioidosis patients who
survived the disease (median 87.53, IQR 63.71–118.80) compared
to those who died (median 60.39, IQR 39–113.30, p = 0.03)
and healthy controls (median 18.60, IQR 16.09–46.29, p < 0.001,
Figure 1A).
We subsequently measured the amount of live B. ps inside of
THP-1-derived macrophages upon ADCP using a conventional
colony count method. The bacterial uptake when using serum
from survivors (median 1.6× 103 CFU/ml, IQR 1.1× 103-2.5×
103 CFU/ml) was significantly higher compared to using serum
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FIGURE 2 | Comparison of intracellular bacterial growth inhibition assay (GIA)
in THP-1 derived macrophages. (A) GIA using serum from acute melioidosis
patients who survived the disease (upward open triangles), acute melioidosis
fatal cases (downward open triangles), and healthy endemic controls (open
circle). (B) GIA using purified IgG antibodies from acute melioidosis patients
who survived the disease (upward open triangles) and acute melioidosis fatal
cases (downward open triangles). The result is expressed as fold change in
CFU/ml at 7 h post-infection compared to 3 h post-infection. The statistical
test used for comparison is the Kruskal-Wallis one-way ANOVA for more than
two groups, and Mann-Whitney U for two groups.
from non-survivors (median 1.2× 103, IQR 0.7× 103-1.8× 103,
p= 0.02) and healthy controls (median 1.1× 103, IQR 0.9× 103-
1.4× 103, p= 0.03, Figure 1B).
Intracellular Bacterial Survival Is Enhanced
in The Presence of Serum From Fatal
Cases Compared to Survivors
We next determined the effect of serum on intracellular bacterial
survival in THP-1-derived macrophages. We measured the
growth rate of bacteria after a 3-h incubation period. We found
that intracellular growth rates of B. ps inside humanmacrophages
were significantly higher in the presence of serum from non-
survivors (median 10.88, IQR 5.42–14.88) when compared to
serum from survivors (median 7.89, IQR 5.58–10.85, p = 0.04)
and healthy donors (median 6.04, IQR 3.22–7.87, p = 0.01,
Figure 2A).
Next, we performed an intracellular growth inhibition assay
using total IgG individually purified from patients to remove
other plasma proteins and components that may affect the result.
There is a borderline evidence showing that the intracellular
growth rate of B. ps inside human macrophages was higher in the
presence of purified IgG from non-survivors (median 6.36, IQR
3.36–8.29) when compared to IgG from survivors (median 4.96,
IQR 2.80–7.5, p= 0.09, Figure 2B).
DISCUSSION
In this study, we assessed the functional role of antibodies
in protection against death from acute melioidosis. We found
that serum from acute melioidosis patients who survived the
disease showed significantly enhanced uptake of live B. ps to
be engulfed by THP-1-derived macrophages compared to those
from non-survivors. Moreover, the serum from survivors also
diminished intracellular growth of B. ps in macrophages after
phagocytosis. These results reveal a significant contribution
of humoral immune responses in protection against death in
human melioidosis.
Although statistical significance was not achieved, purified
IgG individually purified from survivors seems to enhance
intracellular bacterial growth inhibition when compared to IgG
from non-survivors. This result relates to the total IgG level in
serum. Borderline P-value of 0.09 in this study probably due
to an insufficient number of samples, hence replicate trial with
increased number of samples should be conducted to confirm
this finding. In addition, the purified IgG from survivors and
non-survivors seems to enhance intracellular growth inhibition
activity compared to serum samples. This result was probably
due to the higher quantity of antibodies in the assay system when
using purified IgG. The concentration of IgG in serum of general
adult population varies at different age ranging from 400 to 2,200
mg/deciliter blood (Gonzalez-Quintela et al., 2008). We need to
measure the concentration of total IgG in serum of melioidosis
patients to confirm this explanation.
In separate study, we found that the serum level of total
IgG and IgM was not significantly different between survivors
and non-survivors (Chaichana et al., submitted manuscript).
However, we did find that the level of IgG2 subclass was
significantly higher in patients who survived the disease
compared to those who did not. Previous studies demonstrated
that the IgG2 level was associated with protective immunity
(Zarei and Redwan, 2019) and defense against recurrence of
capsulated bacterial infections (Kralickova et al., 2017; Yamazaki
et al., 2019). Follow up work includes a comparison between
the intracellular bacterial growth rate of live B. ps pre-opsonized
with purified IgG2 antibodies derived from survivors and non-
survivors.
Both ADCP activity and intracellular growth inhibition
in this study are complement-independent processes as we
heat-inactivated the serum before use. Therefore, the different
outcomes between serum and purified IgG may be due to
other components in the serum. C-type lectins, which are heat-
resistant plasma opsonins, are also implicated in phagocytosis
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of pathogens via C-type lectin-like receptors on myeloid cells
(Kang et al., 2005; Chiffoleau, 2018). Further analysis of C-
type lectins on opsono-phagocytosis and intracellular growth
inhibition is required.
The ADCP activity of serum from healthy controls with
undetectable anti-B. ps antibodies used to determine the
background level of the assays (Chaichana et al., 2018). We found
that FITC-labeled B. ps pre-opsonized with serum from fatal
cases showed a significantly higher phagocytic index than serum
from healthy controls. Unexpectedly, the phagocytic activity
was comparable between fatal cases and healthy controls when
measuring the number of live bacteria by conventional colony
count. Serum from fatal cases probably results in more FITC-
labeled dead bacteria to be engulfed by macrophages than those
from healthy controls; however further analysis is required to
prove this effect.
Serum from patients who survived melioidosis increased B.
ps uptake and diminished the intracellular growth in THP-
1-derived macrophages, but the macrophages could not clear
the bacteria. This result was similar to a previous study in
a mouse model in which pre-opsonization of B. ps with
B. ps LPS- and capsule-specific IgG increased uptake, but
did not promote clearance in primary murine macrophages
(Mulye et al., 2014). THP-1 cells are derived from tumor
cells that are not equivalent to those of macrophages obtained
from circulating monocytes in terms of their phenotypic
and molecular properties (Kohro et al., 2004; Chaichana
et al., 2017). In addition, the THP-1-derived macrophages
used in our study were in a naïve, not-activated, M0-like
state which is characterized by slower production of reactive
oxygen species (ROS) upon phagocytic stimulation when
compared to an IFN-γ-activated M1-like state (Mendoza-
Coronel and Ortega, 2017). Therefore, we need to further
evaluate the intracellular bacterial growth inhibition of serum
or antibodies comparing primary human and THP-1-derived
macrophages activated with LPS or IFN-γ to become pro-
inflammatory classical M1 macrophages that have high capacity
for bacterial killing.
We found that antibodies from some non-survivors have
a higher phagocytic index value than survivors, but these
antibodies have low or moderate potential to inhibit intracellular
bacterial growth in macrophages. This result implies that the
antibodies may use distinct mechanism between bacterial uptake
and intracellular killing. Moreover, it is also possible that some
patients who do not survive in spite of a strong functional
antibody response may suffer from other contributing factors
in the disease pathway, such as high inoculating pathogen
burden, late presentation, poorer T cell responses, or undetected
underlying comorbidities.
To our knowledge, this is the first report demonstrating
that intracellular bacterial growth inhibition in macrophages is
one of the important mechanistic roles of serum in protection
against death in human melioidosis. Replication in independent
melioidosis cohorts is required to confirm these antibody
functions. The antigenic targets of these functional antibodies
also need to be identified for development of effective antibody-
based vaccines. The in-vitro ADCP and intracellular growth
inhibition assays from this study offer a powerful tool to assess
the efficacy of vaccine candidates against melioidosis in animal
models and vaccine trials.
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